David Scheinberg
Directeur/Bestuurslid bij SELLAS LIFE SCIENCES GROUP, INC.
Vermogen: 6 965 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Angelos Stergiou | M | 48 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 18 jaar |
Barry Kappel | M | 48 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 15 jaar |
Robert van Nostrand | M | 67 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
Cary Sucoff | M | 71 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 14 jaar |
Nicholas J. Sarlis | M | 59 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 4 jaar |
Jane Wasman | F | 67 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
John Varian | M | 64 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
David Mims | M | 60 | 5 jaar | |
Stephen F. Ghiglieri | M | 63 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
Lorraine Gudas | F | - |
Weill Cornell Medical College
| - |
Costantino Iadecola | M | - |
Weill Cornell Medical College
| - |
Derace L. Schaffer | M | 76 |
Weill Cornell Medical College
| - |
Hedvig Hricak | M | 77 |
Gerstner Sloan Kettering Graduate School of Biomedical Science
Weill Cornell Medical College
| 24 jaar |
Tyler Jacks | M | 63 |
Commonwealth Cancer Consortium, Inc.
| 3 jaar |
John Burns | M | 39 | 11 jaar | |
Fabio Lopez | M | 49 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
Marie-Josée Kravis | F | 74 |
Sloan-Kettering Institute for Cancer Research
| - |
Katherine Kalin | F | 61 | 2 jaar | |
Donald J. D'Amico | M | - |
Weill Cornell Medical College
| - |
Dragan Cicic | M | 60 | 4 jaar | |
Laurie Glimcher | M | 72 |
Weill Cornell Medical College
Commonwealth Cancer Consortium, Inc.
| 5 jaar |
Howard H. Pien | M | 66 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 8 jaar |
Javier Pinto | M | - |
Weill Cornell Medical College
| - |
Gail J. Roboz | F | - |
Weill Cornell Medical College
| - |
Matt Vander Heiden | M | - |
Commonwealth Cancer Consortium, Inc.
| - |
Richard Pasternak | M | 75 |
Weill Cornell Medical College
| - |
Madelyn Antoncic | M | 71 |
Weill Cornell Medical College
| - |
Dmitri Konon | M | - |
Weill Cornell Medical College
| - |
Francis Barany | M | - |
Weill Cornell Medical College
| - |
Ronald Crystal | M | - |
Weill Cornell Medical College
| - |
Todd Caven | M | 61 |
Weill Cornell Medical College
| - |
Melissa Nirenberg | F | - |
Weill Cornell Medical College
| - |
Ross Levine | M | 52 |
Weill Cornell Medical College
| 17 jaar |
Ngai Chiu Tse | M | 57 |
Weill Cornell Medical College
| - |
Michael Zelefsky | M | 63 |
Weill Cornell Medical College
| 30 jaar |
Felice Schnoll Sussman | M | 54 |
Weill Cornell Medical College
| 11 jaar |
James B Bussel | M | - |
Weill Cornell Medical College
| - |
David Jaffray | M | - |
Commonwealth Cancer Consortium, Inc.
| - |
Sharon J. Parish | M | - |
Weill Cornell Medical College
| - |
Sophie McKenney | F | - |
Weill Cornell Medical College
| - |
Guillermo Torre-Amione | M | - |
Weill Cornell Medical College
| - |
Michel Nussenzweig | M | - |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | - |
Scott T. Tagawa | M | - |
Weill Cornell Medical College
| 17 jaar |
Paul Gould | M | 77 |
Weill Cornell Medical College
| - |
Linda T. Vahdat | M | - |
Weill Cornell Medical College
| - |
Louis Aronne | M | 69 |
Weill Cornell Medical College
| 38 jaar |
R. Gordon Douglas | M | 89 |
Weill Cornell Medical College
| - |
Jeffrey Greenberg | M | 56 |
Weill Cornell Medical College
| - |
Mitchell Blutt | M | 66 |
Weill Cornell Medical College
| - |
Robert Ruffolo | M | 74 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
Alastair J. J. Wood | M | 77 |
Weill Cornell Medical College
| - |
Ajaypal Banga | M | 65 |
Weill Cornell Medical College
| - |
Michael T. Masin | M | 79 |
Weill Cornell Medical College
| 21 jaar |
Ellen Futter | F | 74 |
Gerstner Sloan Kettering Graduate School of Biomedical Science
| - |
Sanford Weill | M | 91 |
Weill Cornell Medical College
| 29 jaar |
Ronald Perelman | M | 81 |
Weill Cornell Medical College
| - |
Stanley Zinberg | M | 89 |
Weill Cornell Medical College
| - |
Paul A. Marks | M | - |
Sloan-Kettering Institute for Cancer Research
| - |
Morton Coleman | M | 81 |
Weill Cornell Medical College
| 38 jaar |
Maurice S. Reznik | M | 69 |
Sloan-Kettering Institute for Cancer Research
| - |
Cheryl Pegus | M | 60 |
Weill Cornell Medical College
| - |
David Helfet | M | 77 |
Weill Cornell Medical College
| - |
Raju S. K. Chaganti | M | 91 |
Gerstner Sloan Kettering Graduate School of Biomedical Science
| - |
Calvin Roberts | M | 71 |
Weill Cornell Medical College
| 42 jaar |
Kenneth A. Buckfire | M | - |
Weill Cornell Medical College
| - |
Chelsea Clinton | M | 44 |
Weill Cornell Medical College
| 12 jaar |
Rajat K. Gupta | M | 75 |
Weill Cornell Medical College
| - |
Daniel L. Lorber | M | 77 |
Weill Cornell Medical College
| - |
Robert Spiegel | M | 73 |
Weill Cornell Medical College
| 11 jaar |
Lewis Cantley | M | 75 |
Weill Cornell Medical College
| 12 jaar |
Richard N. Kolesnick | M | - |
Sloan-Kettering Institute for Cancer Research
| - |
William Goodwin | M | 83 |
Commonwealth Cancer Consortium, Inc.
| - |
Joan H. Weill | F | - |
Weill Cornell Medical College
| - |
Charlie Lieu | F | - |
Commonwealth Cancer Consortium, Inc.
| 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Messinger | M | 49 | 11 jaar | |
Robert A. McKinney | M | 67 | 20 jaar | |
Mark Robert Baker | M | 69 | 14 jaar | |
Steven Gilman | M | 71 | 8 jaar | |
Roger Pomerantz | M | 67 | 9 jaar | |
Robert Nowinski | M | - | 5 jaar | |
Julia Gregory | F | 71 | 4 jaar | |
Angelo William Lovallo | M | 59 | 7 jaar | |
Patrick Fabbio | M | 56 | 5 jaar | |
Nicole S. Williams | F | 79 | 12 jaar | |
Ivan Lustig | M | - |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | 6 jaar |
Sol Barer | M | 76 | 12 jaar | |
Kurt W. Briner | M | 79 | 15 jaar | |
Peter J. Crowley | M | 65 | 10 jaar | |
Gregory M. Torre | M | 71 | 1 jaar | |
Aleksey N. Krylov | M | - | 1 jaar | |
Stephen P. Goff | M | 72 | 20 jaar | |
Ann MacDougall | F | 70 | 1 jaar | |
Daniel Lee | M | 67 |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | 7 jaar |
Sheng Da Zan | M | 61 | - | |
Ann Marie Assumma | F | 70 | - | |
Tage Ramakrishna | M | 49 | - | |
David E. Martin | M | 69 | - | |
Karen Ferrante | M | 66 | 6 jaar | |
Nancy Dong | F | 58 | 10 jaar | |
David Low | M | 65 | 9 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Bermuda | 7 | 7.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- David Scheinberg
- Persoonlijk netwerk